Gilead

Gilead, Merck once-weekly HIV pill succeeds in Phase 3

Gilead Sciences and Merck announced on Sunday that their investigational once-weekly combination pill of islatravir and lenacapavir met its primary efficacy endpoint in two Phase 3 trials, marking a potential milestone in HIV treatment as the first long-acting oral therapy…